ahlam1399
06-16-2015, 02:24 AM
Avalanche eye therapy meets safety goal; vision improvement modest
(Reuters) - Avalanche Biotech**logies Inc's experimental gene therapy for a leading cause of blindness met its primary safety goal in a small mid-stage trial, while staving off vision loss.http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4742f44b/sc/14/mf.gif?resize=1%2C1
http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/1/rc.img (http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/1/rc.htm)
http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/2/rc.img (http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/2/rc.htm)
http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/3/rc.img (http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/a2.img (http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/ach.img (http://adchoice.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/ach.htm)http://pi.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/a2t.imghttp://pi2.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=G8LHsDchFWA:21zQUDZ2ezA:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=G8LHsDchFWA:21zQUDZ2ezA:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=G8LHsDchFWA:21zQUDZ2ezA:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=G8LHsDchFWA:21zQUDZ2ezA:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=G8LHsDchFWA:21zQUDZ2ezA:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/G8LHsDchFWA
(Reuters) - Avalanche Biotech**logies Inc's experimental gene therapy for a leading cause of blindness met its primary safety goal in a small mid-stage trial, while staving off vision loss.http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4742f44b/sc/14/mf.gif?resize=1%2C1
http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/1/rc.img (http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/1/rc.htm)
http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/2/rc.img (http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/2/rc.htm)
http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/3/rc.img (http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/a2.img (http://da.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/ach.img (http://adchoice.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/ach.htm)http://pi.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/a2t.imghttp://pi2.feedsportal.com/r/231123003116/u/49/f/654207/c/35217/s/4742f44b/sc/14/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=G8LHsDchFWA:21zQUDZ2ezA:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=G8LHsDchFWA:21zQUDZ2ezA:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=G8LHsDchFWA:21zQUDZ2ezA:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=G8LHsDchFWA:21zQUDZ2ezA:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=G8LHsDchFWA:21zQUDZ2ezA:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/G8LHsDchFWA